ArticleResearch in pharmaceutical sciences2026
Comparative evaluation of microfluidic-synthesized nano-niosomes versus liposomal and micro-niosomal deferoxamine in murine iron overload models.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Microfluidic technology provides enhanced standardization for formulating nanoencapsulated drugs compared to traditional bulk methodologies. Here, microfluidic nano-niosomal deferoxamine (Nn-DFO) was compared to micro-niosomal (Mn-DFO) and liposomal (L-DFO) formulations synthesized by conventional thin-film hydration. Experimental approach: The formulations were subjected to physicochemical analyses. Findings/Results: Mean particle sizes were 180.89±74.34 nm for L-DFO, 87.06±2.67 nm for Nn-DFO, and 7.41 ± 0.19 μm for Mn-DFO. Encapsulation efficiencies of L-DFO, Nn-DFO, and Mn-DFO formulations were 64.54%, 57.1%, and 70.72%, respectively. The 4-h drug release rates for L-DFO, Nn-DFO, and Mn-DFO formulations were 20.95%, 31.34%, and 26.30%, respectively, compared to 59.46% release from free DFO (F-DFO) within 4 h. Animals treated with F-DFO, L-DFO, Nn-DFO, and Mn-DFO showed significant reductions in the iron content of the liver (45.03%, 49.36%, 41.63%, and 23.52%, respectively). Urinary iron excretion on day 1 Conclusion and implications: Nn-DFO synthesized by the microfluidic approach showed iron chelation efficacy and immediate iron excretion profile comparable to F-DFO, while being superior to Mn-DFO and L-DFO regarding delayed iron excretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.